Outsourcing

3P Biopharmaceuticals, and Oxford University spin-out, SpyBiotech, have signed a vaccine contract manufacturing agreement.

Vetter has moved into new headquarters located in Ravensburg, Germany, and plans to continue its long-term investment for corporate development.

Cambrex has completed the expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.

Following a recent expansion at its Cambridge, MA, facility, the company now houses a new suite of cellular analysis platforms that enhance its exploratory capabilities into oncology, neuroscience, and rare diseases.

The company’s new CytoML Experiment Suite fully automates each stage of the flow cytometry data lifecycle, allowing for clearer data visualization and analysis.

More complex and challenging compounds require a more tailored approach to formulation strategies.

Industry experts discuss challenges and best practices for scaling up manufacturing under a short deadline.

Facility and equipment design are important, but the team and its experience matter most.

Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.

The radiopharmaceutical CDMO is building a new cGMP facility in Springfield, NJ.

CMDO Piramal Pharma Solutions held a grand opening at a facility they acquired in Sellersville, PA.

The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

Thermo Fisher Scientific is increasing access to cry-electron microscopy with the help of contract research organizations.

Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.

CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2.

Experts at Hovione describe progress being made in understanding how to optimize continuous processes for oral solid-dosage drug products.

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

The investment will allow for the expansion of analytical R&D efforts and will support the company’s reference materials business.

The company has launched a residual GMP-compliant test and dual sourcing opportunity designed to increase compliance and reduce risks for ATMP manufacture.

Particle engineering is a useful tool to manipulate API particles into a form that is manufacturable and deliverable to the patient.

COVID-19 has brought to light the issues of European manufacturing capabilities, leading industry to question whether it is now time to reinvest in domestic medicines supply.

Conversations with CMOs/CDMOs about capabilities and how they work to reduce complexities in the supply chain should focus on cost efficiency, temperature excursions, and sustainability.

The right outsourcing partner should open up access to expertise and technical capabilities in a broad range of dosage forms to ensure commercial success.

The early success seen on the market for approved cell and gene therapies poses both technical and manufacturing challenges for pipeline candidates on the road to commercialization.